Recent SEC filings
Insider and ownership filing tracker
Form 4 reports insider transactions. Schedule 13D and 13G filings report certain significant ownership positions. 13F reports institutional holdings when filed by an investment manager. Always open the original filing for context.
Company and financial overview
This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.
Financial performance charts
Annual values from SEC filings. Free cash flow is calculated as operating cash flow less capital expenditures.
Upcoming catalyst timeline
Review the Earnings tab for the expected date and estimates.
PRIMARY DOCUMENT
EMA, RSI, MACD, volume, structure, and key levels update after a completed daily candle.
How the research score works
The overall score is a weighted research judgment covering business quality, fundamental strength, growth catalysts, valuation, technical condition, and downside risk. A high score does not eliminate risk, and a low score does not guarantee poor performance.
Company overview
Amgen is a biotechnology company with a broad portfolio of therapies across inflammation, oncology, cardiovascular disease, and bone health, alongside an emerging pipeline in obesity treatment.
Business model
Amgen earns revenue from a diversified set of biologic drugs, none of which represents an overwhelming share of total sales, which reduces single product concentration risk relative to more narrowly focused biotech peers.
Growth drivers
- Pipeline progress in the obesity drug category
- Continued growth of newer inflammation and oncology therapies
- International expansion of existing product lines
- Biosimilar competition management for legacy products
Competitive position
Amgen's diversified portfolio and manufacturing scale give it more stability than single product biotech companies. Its established relationships with prescribers and payers support continued adoption of both existing and pipeline products.
Risks
Biosimilar competition affects several of its legacy products, pipeline setbacks in the obesity category would remove a key growth catalyst, and drug pricing policy remains an ongoing risk across the biotech industry.
Valuation
Amgen tends to trade as a steady, diversified biotech, with the obesity pipeline representing an optional growth catalyst that could re-rate the stock if trial results are strong.
Final view
Overall rating: 70/100
Amgen's diversification is its main strength relative to peers, reducing reliance on any single drug. My view is balanced, with the obesity pipeline as the primary upside catalyst to watch for.
This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market data is provided by Finnhub and other third-party sources and may be delayed, incomplete, or inaccurate. The author may hold positions in securities discussed, and opinions may change without notice. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.